Market Closed -
Nasdaq
21:30:01 26/04/2024 BST
|
5-day change
|
1st Jan Change
|
1.42
USD
|
-2.07%
|
|
-4.05%
|
-24.47%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
184.4
|
66.28
|
123.9
|
93.55
|
-
|
-
|
Enterprise Value (EV)
1 |
-27.11
|
-73.52
|
-16.84
|
57.05
|
-171.8
|
-8.131
|
P/E ratio
|
-0.37
x
|
-0.93
x
|
-0.95
x
|
-1.03
x
|
-1.04
x
|
-1.14
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
62.4
x
|
0.01
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-115
x
|
-0
x
|
EV / EBITDA
|
0.66
x
|
-
|
0.18
x
|
-0
x
|
0
x
|
0
x
|
EV / FCF
|
0.66
x
|
1.22
x
|
-
|
-0.65
x
|
1.72
x
|
0.09
x
|
FCF Yield
|
150%
|
82.2%
|
-
|
-154%
|
58.2%
|
1,156%
|
Price to Book
|
0.87
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
28,815
|
28,815
|
65,881
|
65,881
|
-
|
-
|
Reference price
2 |
6.400
|
2.300
|
1.880
|
1.420
|
1.420
|
1.420
|
Announcement Date
|
31/03/22
|
14/03/23
|
05/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
1.5
|
10,122
|
EBITDA
1 |
-
|
-41.23
|
-
|
-91.38
|
-95,892
|
-121,887
|
-166,196
|
EBIT
1 |
-
|
-41.23
|
-71.42
|
-91.44
|
-110.7
|
-135.5
|
-145.1
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-9,034.97%
|
-1.43%
|
Earnings before Tax (EBT)
1 |
-
|
-67.81
|
-70.71
|
-85.23
|
-105.1
|
-129.8
|
-139.4
|
Net income
1 |
-14.59
|
-74.99
|
-71.33
|
-86.08
|
-105.1
|
-129.8
|
-139.4
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-8,655.47%
|
-1.38%
|
EPS
2 |
-82.36
|
-17.30
|
-2.480
|
-1.980
|
-1.380
|
-1.365
|
-1.250
|
Free Cash Flow
1 |
-
|
-40.8
|
-60.42
|
-
|
-88
|
-100
|
-94
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-6,666.67%
|
-0.93%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/08/21
|
31/03/22
|
14/03/23
|
05/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-21.4
|
-17.01
|
-18.16
|
-15.86
|
-20.39
|
-17.92
|
-21.85
|
-23.48
|
-28.18
|
-24.53
|
-25.8
|
-27.37
|
-32.23
|
-31.25
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-21.24
|
-17.14
|
-18.39
|
-15.57
|
-19.61
|
-16.64
|
-20.65
|
-22.12
|
-25.83
|
-23.08
|
-24.45
|
-26.12
|
-31.18
|
-28.9
|
Net income
1 |
-21.24
|
-17.2
|
-18.5
|
-15.69
|
-19.94
|
-17.04
|
-21.18
|
-21.68
|
-26.18
|
-23.08
|
-24.45
|
-26.12
|
-31.12
|
-28.9
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.330
|
-0.6000
|
-0.6400
|
-0.5400
|
-0.6900
|
-0.5900
|
-0.7400
|
-0.4300
|
-0.4000
|
-0.3467
|
-0.3700
|
-0.3100
|
-0.3667
|
-0.2600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
31/03/22
|
16/05/22
|
11/08/22
|
09/11/22
|
14/03/23
|
11/05/23
|
11/08/23
|
13/11/23
|
05/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
212
|
140
|
141
|
36.5
|
265
|
102
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-40.8
|
-60.4
|
-
|
-88
|
-100
|
-94
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-63.3%
|
-109,412%
|
-78,813%
|
-87,231%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
7.350
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
0.69
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
09/08/21
|
31/03/22
|
14/03/23
|
05/03/24
|
-
|
-
|
-
|
Last Close Price
1.42
USD Average target price
8.75
USD Spread / Average Target +516.20% Consensus |
1st Jan change
|
Capi.
|
---|
| -24.47% | 93.55M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|